89791-96-8

Basic information

• Product Name: 5-methyl-3-nitrobenzene-1,2-diol
• CAS NO: 89791-96-8
• Molecular Formula: C₇H₇NO₄
• Molecular Weight: 169.1348
• Mol File: 89791-96-8.mol

Chemical Properties

• Boiling Point: 291.8°C at 760 mmHg
• Flash Point: 131.8°C
• Density: 1.478g/cm³
• Vapor Pressure: 0.00109mmHg at 25°C
• Refractive Index: 1.643
• CAS DataBase Reference: 5-methyl-3-nitrobenzene-1,2-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methyl-3-nitrobenzene-1,2-diol(89791-96-8)
• EPA Substance Registry System: 5-methyl-3-nitrobenzene-1,2-diol(89791-96-8)

Safety Data

• Hazardous Substances Data: 89791-96-8(Hazardous Substances Data)

Upstream product

• 452-86-8 4-methyl-1,2-dihydroxybenzene 
• 1688-19-3 2-methoxy-5-methylphenyl acetate 
• 93-51-6 2-Methoxy-4-methylphenol 
• 53411-80-6 2-methoxy-4-methyl-6-nitrophenol 

Downstream Products

• 89677-97-4 2-Hydroxy-5-methyl-3-nitro-benzochinon-(1,4) 
• 78380-78-6 3,4-dimethoxy-5-nitro-toluene 

Relevant articles and documents

Gas-phase IR cross-sections and single crystal structures data for atmospheric relevant nitrocatechols

The gas-phase IR absorption cross sections for 3-nitrocatechol, 5-methyl-3-nitrocatechol, 4-nitrocatechol and 4-methyl-5-nitrocatechol were evaluated using the ESC-Q-UAIC (the environmental simulation chamber made of quartz from the “Alexandru Ioan Cuza” University of Iasi, Romania) photoreactor facilities. Specific infrared absorptions and integrated band intensities in the range of 650–4000 cm?1 were investigated by long path gas-phase FT-IR technique. Two different addition methods (solid and liquid transfer methods) of nitrocatechols into the reactor were employed in these investigations. All investigated nitrocatechols were synthesized and characterized by X-ray diffraction spectroscopy techniques beside traditional nuclear magnetic resonance (NMR) and infrared (IR) spectroscopy in order to evaluate their structure-properties relationship in gas and solid phase. This study reports for the first time the gas-phase infrared cross sections and the X-ray diffraction analysis for (methyl) nitrocatechols.

Pyrimidine derivatives Anaplastic lymphoma kinase inhibitors

The invention belongs to the technical filed of medicines, and concretely relates to pyrimidine derivative anaplastic lymphoma kinase inhibitors represented by general formula (I), or stereoisomers, or pharmaceutically acceptable salts or esters or solvat

POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR

Provided is a polycyclic inhibitor of anaplastic lymphoma kinase as represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, and ring A are as defined in the description. The invention also relates to a method for preparing the compound, a pharmaceutical preparation and a pharmaceutical composition comprising the compound, and use of the compound, the pharmaceutically acceptable salt or stereoisomer thereof in manufacture of a medicament for the treatment and/or prevention of an anaplastic lymphoma kinase-mediated cancer or non-cancer related diseases.

Triazine derivative anaplastic lymphoma kinase inhibitor

The invention belongs to the technical field of medicines, and particularly relates to a triazine derivative anaplastic lymphoma kinase inhibitor shown in a general formula (I), pharmaceutically acceptable salt, ester, solvate or stereoisomer of the inhibitor. R1, R2, R3, R4, R6, R7 and A rings are defined in the description. The invention further relates to a preparation method of compounds, a medicinal preparation containing the compounds, a medicine combination containing the compounds and an application of the compounds, the pharmaceutically acceptable salt, ester, solvate or stereoisomer to preparation of a medicine for treating and/or preventing anaplastic lymphoma kinase-mediated cancer-related diseases.